contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Economist

Marianne Palmu

Analyst

Kaisa Vanha-Perttula

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Posting this here as well: @Marianne_Palmu and @Kaisa_Vanha-Perttula added Orion to the Femme Portfolio.                    Inderes              Femmesalkku: Orionin tie tähtiin - Inderes    Avasimme tänään uuden position suomalaisessa lääkejätissä, kun ostimme Orionia 15 %:n painolla Femmesalkkuun.

On Orion’s outlook and stock pricing: “Despite high expectations, Orion’s share is not yet particularly expensive, and not necessarily even fully priced. The valuation of the share, which has strengthened by nearly 40 percent over the year, has tightened, but the pricing has not become excessive.”                   Tärkeimmät talousuutiset | Kauppalehti – 26 Jan 26              Pörssissä loistava Orion varautuu jo hittilääkkeen patenttien raukeamiseen –...    Orion kertoi uusia arvioita hittituote Nubeqan myyntiluvuista ja julkisti arvionsa vuoden 2026 tulosluvuista. Toimitusjohtaja Liisa Hurmeen mukaan Nubeqan patenttien raukeamiseen varaudutaan jo nyt usealla eri tavalla. Hurme muistuttaa, että Orion on...

Nubeqa’s patent protection is expected to remain in effect beyond 2030. Xtandi, which is Nubeqa’s direct competitor in the US prostate cancer market, currently holds the largest market share and is expected to face generic competition at the end of 2027, which will likely lead to a significant price reduction for Xtandi. In this situation, would it be reasonable to assume that pricing pressure on Nubeqa could begin as early as the end of 2027, well before the expiration of its own patent protection, if Bayer is forced to lower its price to defend its market share against a cheaper generic competitor?

Here is the data I was recalling from memory in the interview:

I personally see Orion’s major risk lying in acquisitions. They might buy some drug development company at a high price, only for the drug to ultimately fail. Of course, their own drug development doesn’t always succeed either. So while everything looks good now, there are risks along the way.

This was a good overview of the long-term outlook: -One could say that until around the turn of the 2020s and 2030s, aided by Nubeqa and the expansion of its indications, massive amounts of money will be pouring into Orion from all sides.  -Then the patents for this drug will expire by the mid-2030s, and new products may emerge from the R&D pipeline.  -It should also be noted that currently, all of Orion’s divisions are in quite good shape, meaning no catastrophe is in sight, even if the R&D pipeline doesn’t produce a new blockbuster hit.  -The information in the report was interesting: the impact of an expiring patent starts to show in the company’s stock pricing 4–6 years before the actual expiration. In Orion’s case, this would mean the very end of the 2020s, but at the same time, the expansions of Nubeqa’s indications might materialize. So, would this create an offset?  -I was left wondering where all that money pouring in will be invested: acquisitions, implementing the global strategy, extra dividends, or what? My guess is that something will happen on this front, meaning we will see some new initiatives from the company in the coming years.  -The timing of this video’s release was relevant in that the trade war scenario discussed in it landed right in our laps immediately. This morning’s news cycle from the US reported that Trump has set his sights on those pharmaceutical companies that haven’t yet reached an agreement with him on drug price reductions. These include, among others, Bayer/Orion. So, it’s not out of the question that “more is to follow” and we’ll soon need to create new future projections for Orion as well.

Siltanen’s thoughts on Orion and Nubeqa’s strong momentum can also be heard in a new video filmed today.  “The success of the cancer drug Nubeqa is like a story written in the stars. Orion estimates its share of Nubeqa sales will exceed the one billion euro mark by the end of the decade. The stock is at all-time highs and growth drivers are in place, but where will future returns be built from when Nubeqa’s patent protections eventually expire?”                   Inderes              Orion: Tähtiin kirjoitettu menestyslääke - Inderes    Aika: 16.01.2026 klo 15.55 Syöpälääke Nubeqan menestys on kuin tähtiin kirjoitettu tarina. Orion arvioi osuutensa Nubeqan myynnistä ylittävän miljardin euron rajan vuosikymmenen lopulla.                             Topics:  00:00 Introduction  00:23 Nubeqa sales are only accelerating  02:02 Strong earnings leverage  02:41 Long-term return potential  03:57 Political and regulatory risks in the United States  05:45 What after Nubeqa?  09:25 Is Orion still cheap?

Orion

Vi åbnede i dag en ny position i den finske medicinalgigant, da vi købte Orion med en vægt på 15 % til Kvindernes Portefølje.


<p><em>Automatisk overs&#xe6;ttelse: Oprindeligt udgivet p&#xe5; finsk 28.1.2026, 12.12 GMT. Giv feedback <a href="https://forum.inderes.com/t/inderes-fi-sisallon-kehitysideat/71/?tl=da">her</a>.</em></p><p>Vi &#xe5;bnede en ny position i den finske medicinalgigant, da vi k&#xf8;bte Orion med en v&#xe6;gt p&#xe5; 15 % til Femmesalkku. Orion er p&#xe5; vej mod stjernerne, drevet af Nubeqa, der er udviklet til behandling af prostatakr&#xe6;ft. Aktiens v&#xe6;rdians&#xe6;ttelse underst&#xf8;ttes is&#xe6;r af Nubeqas nyligt styrkede langsigtede indtjeningsv&#xe6;kstforventninger samt et udbytteafkast p&#xe5; 2,4 %. V&#xe6;rdians&#xe6;ttelsen kan dog ikke betragtes som billig, men Nubeqas udvikling har gentagne gange overrasket, og salgsh&#xf8;jdepunktet kan stadig overraske med sin h&#xf8;jde omkring &#xe5;rtiets udgang.</p>
<div>
<div lang="fi">
<div>
<p><em>Femmesalkku blev etableret med en startkapital p&#xe5; 20.000 EUR i for&#xe5;ret 2025. Vores portef&#xf8;lje er baseret p&#xe5; indenlandske og udenlandske selskaber og fonde af h&#xf8;j kvalitet, der har varige konkurrencefordele og skaber aktion&#xe6;rv&#xe6;rdi, hvilket tilsammen muligg&#xf8;r den &#xf8;nskede diversificering p&#xe5; lang sigt.</em></p>
</div>
</div>
</div>

	2024	25e	26e
Revenue	1,542.4	1,912.8	1,919.7
growth-%	29.7 %	24.0 %	0.4 %
EBIT (adj.)	416.5	639.4	639.9
EBIT-% (adj.)	27.0 %	33.4 %	33.3 %
EPS (adj.)	2.35	3.59	3.62
Dividend	1.65	1.70	1.75
Dividend %	3.6 %	2.4 %	2.5 %
P/E (adj.)	19.5	19.7	19.6
EV/EBITDA	10.4	14.3	13.8

Femmesalkku: Orions vej til stjernerne

Stay up to date

Key Estimate Figures14.01

Forum discussions